Joint Research with FUJIFILM to Create Immuno-Oncology Drugs
First written in FY2017. 1 of 3 entries say "Restated". Latest entry: FY2021.
The whole theme swung hardest in 2022: 1 of 7 companies on the "Worse" side.
0 other companies' latest entry also says "Dropped".
- FY2021DroppedAnnual report
「The company is also conducting joint research with the University of Tokyo Hospital and the Pharma Valley Project (Fujinokuni Medical Castle Town Promotion Organization and Shizuoka Prefectural University) to create next-generation compounds as described above.」
The current filing's discussion of joint research lists the University of Tokyo Hospital, the Pharma Valley Center project and the University of Shizuoka, but does not mention the joint research with FUJIFILM Corporation referred to in the previous filing. - FY2020RestatedAnnual report
「The company is also conducting joint research with the University of Tokyo Hospital, the Pharma Valley Project (Fujinokuni Medical Castle Town Promotion Organization and Shizuoka Prefectural University), and FUJIFILM Corporation to create next-generation compounds as described above.」
The company continues joint research with FUJIFILM Corporation aimed at discovering immunotherapeutic anticancer drugs. - FY2017First statedAnnual report
「In June 2017, the company entered into a joint research agreement with FUJIFILM Corporation to discover new immunotherapeutic anticancer drugs.」
The company entered into a joint research agreement with FUJIFILM Corporation to discover new immunotherapeutic anticancer drugs.